Home Self Admin denied as not medically necessary by Humana?

Humana's specific coverage criteria for home self admin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Home Self-Administration as Not Medically Necessary — and How to Appeal

A medical-necessity denial on home self-administration means Humana concluded that the patient's clinical situation does not require self-administration at home — in other words, that facility-based infusion or administration would be equally appropriate. These denials are often driven by utilization-management criteria that default to facility administration as the "least intensive setting" without accounting for the individual patient's clinical or logistical circumstances.

### Why This Denial Is Appealable

Medical necessity is an individualized determination. The treating physician, not the plan, is best positioned to assess whether home administration is necessary given the patient's condition, functional status, distance from infusion facilities, infection-exposure risk, vein access challenges, or documented need for more frequent dosing that makes repeated facility visits impractical. Appeals that center on the prescriber's individualized clinical judgment and document specific patient-level factors are more likely to succeed than generic requests.

### Federal Appeal Rights

• Internal appeal: File within the timeframe specified on the denial notice. Humana must respond within 30 days for standard pre-service requests.
• External review (ACA §2719 / ERISA §503): After a final internal denial you may request an independent external review, generally within four months of the denial. An independent clinical reviewer — unaffiliated with Humana — will assess whether the denial was consistent with generally accepted medical standards.
• Expedited review: If the standard timeline would seriously jeopardize the patient's health or ability to regain maximum function, request expedited review; decisions typically required within 72 hours.

### Documentation to Gather

1. Diagnosis and current clinical status: Specialist notes confirming the diagnosis and current disease status, including any factors (e.g., venous access difficulty, immunocompromise, mobility limitation) that make facility visits problematic. 2. Prescriber medical-necessity letter: A detailed letter from the treating physician explaining why home self-administration is medically necessary for this specific patient — not merely convenient — and addressing any factors that make facility-based administration inferior or harmful for this individual. 3. Prior facility-administration records (if applicable): Notes documenting complications, adverse reactions, or practical barriers experienced during facility administration. 4. Distance and access documentation: If geographic access to infusion facilities is a barrier, include documentation (e.g., travel time, availability of certified infusion centers). 5. Training and safety documentation: Evidence that the patient has been or will be trained in home self-administration technique, supporting clinical appropriateness.

### Criteria-Mapping Structure

Obtain Humana's current published medical-necessity policy for home self-administration of the relevant drug. Copy each criterion. For each one, provide the specific chart fact or clinical circumstance that satisfies it. Pay particular attention to any criteria addressing clinical stability, prior facility administration, or documented barriers to facility care — these are the axes on which medical-necessity home-admin appeals most often turn.

Verify the exact medical-necessity criteria against Humana's current published coverage policy and the FDA-approved prescribing information for the drug.